Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
| Excerpt | Reference |
|---|
| "An increased rate of chromosome aberrations was found in all treated cultures." | ( Banerjee, A; Huang, CC; Jung, O, 1977) |
| "The distribution of chromosomal aberrations between and within chromosomes of male D, melanogaster somatic cells after treatment with UV has been analyzed." | ( Gatti, M; Olivieri, G; Pignone, D; Pimpinelli, S; Santini, G, 1977) |
| "A significantly increased frequency of chromosomal aberrations was found in lymphocytes from eight psoriatic patients previously treated with arsenic than in lymphocytes from eight psoriatics with no such previous treatment." | ( Beckman, G; Brun, E; Nordenson, I; Salmonsson, S, 1979) |
| "Potentiation of chromosome aberrations was observed when the anthramycin-treated cells were post-treated with caffeine." | ( Dosik, H; Ved Brat, S; Verma, RS, 1979) |
| "Incidence of chromosome aberrations by the treatment with these mycotoxins correlated fairly well with their mutagenic activity." | ( Saito, M; Tsutsui, T; Umeda, M, 1977) |
| "Marked chromosomal abnormalities were observed in cells of embryos of animals treated with AF-2 at over 20 mg/kg." | ( Inui, N; Nishi, Y; Taketomi, M, 1978) |
| "No enhancement of chromosome aberrations could be observed after acute treatment of early primary spermatocytes or chronic treatment of spermatogonia with INH." | ( Adler, ID; Müller, D; Perret, R; Rathenberg, R; Schmaltz, A; Strasser, FF, 1978) |
| "Abnormal amounts of chromosome aberrations were not found, and the frequency of sister chromatid exchange (examined at the last treatment) was not increased." | ( Brøgger, A; Thune, P; Waksvik, H, 1978) |
| "The rate and type of chromosomal aberrations in the bone marrow cells and circulating lymphocytes of the gamma-irradiated monkeys prophylactically treated with cystamine and mexamine 5-10 minutes before the irradiation was studied." | ( Kosichenko, LP; Semenov, LF, 1975) |
| "No significant chromosome aberrations were seen in the treated groups with MS-4101, diazepam, and nitrazepam when compared with the nontreated control." | ( Ishimura, K; Neda, K; Sato, H; Sawai, M; Yamamoto, K, 1977) |
| "Structural chromosome aberrations were present in the recovery period of more than 12 h following a treatment of 1 h with 10(-4) mol/l CdSO4." | ( Bauchinger, M; Röhr, G, 1976) |
| "Analysis of the effect of NaF on chromosome aberrations induced by Trenimon revealed that pre-, simultaneous and post-treatments significantly enhanced the frequency of undamaged mitoses." | ( Obe, G; Slacik-Erbn, R, 1976) |
| "Gross chromosomal aberrations were assessed in human leucocyte cultures and in bone marrow preparations from drug-treated mice." | ( Ellis, JH; Holden, HE; Hyneck, ML; Ray, VA, 1975) |
| "The frequency of chromosomal aberrations induced by adriamycin was studied in the mitotic as well as in the prematurely condensed chromosomes (PCC) of the treated cells." | ( Hittelman, WN; Rao, PN, 1975) |
| "The frequency of cells presenting chromosome abnormalities was determined in patients with schistosomiasis before and after treatment with a single dose of 2." | ( Chamone, DA; Da Silva, LC; Ferreira, NR; Frota-Pessoa, O; Moro, AM; Otto, PA; Pedroso, MB, 1975) |
| "The frequencies of cells with chromosome aberrations after the treatment with MC at a 5 mg/kg dose were 54,4%; 41,8%; 40,4% and 26,8% in 101H, B6, C3H/Sn mice and in the F1 hybrids (C3HX101) respectively." | ( Malashenko, AM; Surkova, NI, 1975) |
| "A marginal increase in the frequency of chromosome aberrations was observed following treatment with 3-AB in controls as well as in patient groups." | ( D'Souza, D; Das, BC; Thomas, IM, 1992) |
| "The level of structural chromosomal aberrations two years after the therapeutic treatment was 0." | ( Iakovleva, TK; Moiseenko, VM; Monakhov, AS, 1992) |
| "It has previously been reported that chromosome aberrations induced by ultraviolet (UV) radiation can be enhanced by treatment with sodium arsenite for 24 h post-irradiation." | ( Huang, CF; Huang, H; Huang, JS; Jan, KY; Wang, TC, 1992) |
| "The frequency of chromosome aberrations induced by simultaneous treatment with MMS at a concentration of D20 and EMS at various concentrations for 3 h was additive." | ( Kojima, H; Konishi, H; Kuroda, Y, 1992) |
| "X-Ray-induced chromosomal aberrations (CA) were potentiated by post-treatments in G2 with either caffeine (caff) or poly-D-lysine (PDL) in root-tip cells of Allium cepa." | ( Cortés, F; Mateos, JC; Mateos, S; Panneerselvam, N, 1992) |
| "No significant increases in structural chromosome aberrations (CA) were found either when the paracetamol group (male, female or both) post-dosing values were compared with pre-dosing values, or when treated groups at any sampling time were compared with the placebo groups." | ( Baumeister, M; Dresp, JH; Gerloff, C; Gocke, E; Kirkland, DJ; Marshall, RR, 1992) |
| "More micronuclei and chromosomal aberrations in mouse bone marrow cells were induced by multiple than by single treatment." | ( Hirabayashi, K; Kasahara, Y; Makita, T; Miura, D; Nakai, Y; Yagi, K, 1992) |
| "Sister chromatic exchanges (SCE) and chromosome aberrations (CA) in mice after in vivo exposure of Green S were carried out following single acute treatment." | ( Giri, AK; Khan, KA; Sethi, N; Sivam, SS, 1992) |
| "The frequency of chromosome aberrations in the peripheral blood of patients successfully treated for Hodgkin's disease (HD) and non-Hodgkin's lymphoma is compared with that seen in age-matched haematologically normal subjects." | ( Clark, RE; Jacobs, A; Jones, BM; White, AD, 1992) |
| "The frequencies of chromosomal aberrations induced were scored in first post-treatment metaphases." | ( Johannes, C; Obe, G, 1991) |
| "Sister chromatid exchanges and chromosome aberrations were analyzed in peripheral blood lymphocytes of six newborns 24 h after intramuscular administration of 1 mg vitamin K1 and in six control neonates." | ( Cornelissen, M; De Abreu, R; Kollee, L; Merkx, G; Monnens, L; Smeets, D, 1991) |
| "There were no significant elevations in chromosome aberrations at these post-treatment sample times." | ( Ammenheuser, MM; Au, WW; Belli, JA; Ward, JB; Whorton, EB, 1991) |
| "The frequency of chromosomal aberrations induced was directly proportional to the concentration of the chemical administered." | ( Ghosh, A; Sharma, A; Talukder, G, 1991) |
| "The frequency of SCEs and chromosome aberrations induced by mitomycin C (MMC) or UV was enhanced by the posttreatment with tea tannin components." | ( Imanishi, H; Kato, T; Ohta, T; Sasaki, YF; Shirasu, Y; Watanabe, M, 1991) |
| "The frequencies of chromosome aberrations and sister chromatid exchanges (SCEs), cell proliferation kinetics and mitotic indices were studied in peripheral blood lymphocyte cultures of leprosy patients both before and after chemotherapy." | ( D'Souza, D; Das, BC; Thomas, IM, 1991) |
| "Thus, the ratio of micronuclei to total chromosome aberrations in secondary spermatocytes was always higher in colcemid-treated cells compared to adriamycin-treated cells following 18- and 42-h treatment periods." | ( Pohorenec, GM; Risley, MS, 1991) |
| "The induction of chromosomal aberrations and sister-chromatid exchanges (SCE) was studied in human lymphocyte cultures treated with chloramphenicol (CAP), an antimicrobial agent acting by inhibiting protein synthesis." | ( Caretto, S; Loprieno, N; Rainaldi, G; Sbrana, I, 1991) |
| "The number of chromosomal aberrations and SCE were increased upon treatment, but only transiently, returning to basal levels between consecutive treatments." | ( Gebauer, HJ; Küster, W; Meschig, R; Peterseim, UM; Plewig, G, 1991) |
| "Sister-chromatid exchange (SCE) and chromosome aberrations have been studied in peripheral lymphocytes of 20 epileptic children treated in monotherapy with valproic acid (VPA) for 6-52 months and in 2 matched control groups." | ( Hu, LJ; Huang, YQ; Lu, BQ; Lu, XF, 1990) |
| "The incidence of chromosomal aberrations was monitored till day 32 after AFB1 administration." | ( Bárta, I; Petr, T; Turek, B, 1990) |
| "The level of chromosomal aberrations was compared with that found in aphidicolin-treated cultures from 12 normal subjects of the same age." | ( Caporossi, D; Nicoletti, B; Tedeschi, B; Vernole, P, 1990) |
| "However, no significant induction of chromosome aberrations was detected in cells treated with Fe-NTA up to 100 micrograms Fe/ml of the drug even after treatment for 3 days." | ( Nakatsuka, S; Namba, M; Tanaka, H, 1990) |
| "MCHT resulted in no increases in chromosome aberrations in cultured human lymphocytes, with or without S9 fraction, neither was there any increase in micro-nucleated polychromatic erythrocytes in treated mice." | ( Asquith, JC; Dewey, J; Lee, CG; Morris, BC; Webber, TD, 1990) |
| "These lymphocytes showed higher chromosomal aberrations in comparison with lymphocytes isolated from the patients before treatment." | ( Baharav, E; Friedman, J; Halbrecht, I; Sandowski, U; Shabtai, F, 1990) |
| "The greatest frequency of chromosomal aberrations was detected 12 h after treatment." | ( Balbueno, RA; Erdtmann, B; Gimmler-Luz, MC, 1990) |
| "Hypotonic treatment alone induced chromosomal aberrations (CA), leading to very high frequencies at low osmolalities (50 mOsm/kg H2O)." | ( Nowak, C, 1990) |
| "Unstable chromosome aberrations were scored in peripheral blood lymphocytes (PBL) serially collected from 21 breast cancer patients before and after radiotherapy (RT), chemotherapy (CT) and combined treatments." | ( Doloy, MT; Duranton, I; Guedeney, G; Leroy, A; Magdelenat, H; Rigaud, O, 1990) |
| "Karotype studies showed several chromosomal abnormalities following radiotherapy." | ( Albert, DM; Cassady, JR; Leombruno, D; Little, JB; Puliafito, CA; Trantravahi, R; Walton, DS; Weichselbaum, RR, 1986) |
| "SN-07 also induced chromosomal aberrations and a forward mutation (6-TGr) in Chinese hamster V79 cells after 1 h treatment at 12." | ( Ishida, S; Kawanishi, G; Kishi, T; Miyata, N; Yajima, N, 1989) |
| "Inducibility of chromosome aberrations of the cells following treatment with sodium fluoride was also dependent upon the phase of cell cycle." | ( Suzuki, N; Tsutsui, T, 1989) |
| "The induction of chromosomal aberrations and sister-chromatid exchanges (SCE) was studied in human lymphocyte cultures treated with camptothecin (CM), an inhibitor of mammalian topoisomerase I." | ( De Salvia, R; Degrassi, F; Palitti, F; Tanzarella, C, 1989) |
| "For studying chromosomal aberrations mice were treated both acutely (single treatment) and subacutely (for 5 consecutive days) with 3 dose levels of Curacron, 12, 36 and 72 mg/kg." | ( Abdou, HE; de Hondt, HA; el Nahas, SM, 1989) |
| "In contrast, chromosomal aberrations increased a little during the 60 min after treatment in both GSH- and GSH+ cells." | ( Ochi, T, 1989) |
| "Caprolactam (CAP) induced chromosome aberrations in whole-blood cultures of human lymphocytes at 50 mM without metabolic activation (24-h treatment) and at 200 mM in the presence of rat liver S9 mix (1-h treatment)." | ( Järventaus, H; Norppa, H, 1989) |
| "The induction of chromosomal aberrations by PQ was enhanced by a 1-h pretreatment with diethyldithiocarbamate, an inhibitor of superoxide dismutase." | ( Ishidate, M; Sofuni, T, 1988) |
| "Although no significant chromosomal aberrations or sister chromatid exchanges (SCE) were found in asbestos treated cultures, a significantly higher number of SCEs was observed in cells treated with both asbestos and radiation compared to cells receiving radiation alone." | ( Geard, CR; Hei, TK; Osmak, RS; Travisano, M, 1985) |
| "The induction of chromosome aberrations by exposing sperm or oocytes to X-rays was remarkably potentiated by post-treatment incubation in the presence of each of the 3 inhibitors." | ( Matsuda, Y; Tobari, I, 1989) |
| "The induction of chromosomal aberrations in rat pleural mesothelial cells (RPMC) following in vitro treatment with chrysotile fibres has been demonstrated." | ( Bignon, J; Jaurand, MC; Kheuang, L; Magne, L, 1986) |
| "The frequencies of chromosomal aberrations induced by the restriction endonuclease Alu I (recognition site AG/CT) can be elevated to a similar extent by additional treatments with a single-strand-specific endonuclease from Neurospora crassa (EC 3." | ( Kamra, OP; Obe, G, 1986) |
| "In 4 patients showing clonal chromosomal abnormalities before treatment a disappearance of minor clonal abnormalities during treatment was observed, and in 3 chromosomal abnormalities reappeared after cessation of therapy." | ( Bendix-Hansen, K; Ellegaard, J; Hokland, P; Kerndrup, G; Pedersen, B, 1987) |
| "The formation of chromosome aberrations induced by alkylating agents such as mitomycin C has been shown to require the passage of the treated cell through S phase." | ( Hittelman, WN; Sognier, MA, 1986) |
| "A significant increase in the chromosomal aberrations was observed for all the dyes and in the nitrite treated series when compared with distilled water controls." | ( Das, SK; Giri, AK, 1988) |
| "In the meiotic cells, the incidences of chromosome aberrations increased significantly with the highest dose and with the longest period of treatment." | ( Das, RK; Roy, B, 1988) |
| "Statistically significant increases of chromosome aberrations in bone marrow cells occurred after single treatment (500 and 2000 mg/kg body wt) when chromatid gaps were included and after multiple treatment (250 and 500 mg/kg) when they were excluded." | ( Beçak, W; Pereira, CA; Ribeiro, LR; Salvadori, DM, 1988) |
| "Bone marrow chromosome aberrations were not dose, time or route dependent, but most of the results differed significantly from controls except after 6 and 24 h of treatment using the i." | ( Bhunya, SP; Pati, PC, 1988) |
| "The frequency of chromosomal aberrations in a cohort of 50 patients with ovarian carcinoma was increased for up to ten years after melphalan therapy." | ( Einhorn, N; Holmberg, K; Lambert, B, 1986) |
| "Reduction of the induced chromosomal aberrations was obtained in cells pretreated with interferons." | ( Andronova, AV; Shvetsova, TP; Vasil'eva, IM; Zasukhina, GD, 1987) |
| "The induction of structural chromosome aberrations and sister chromatid exchanges (SCE) was studied in human lymphocytes in vitro after treatment with the two bifunctional furocoumarins 5-methoxypsoralen (5-MOP) and 8-methoxypsoralen (8-MOP) in the presence of UV-A." | ( Abel, G, 1987) |
| "it also caused chromosomal aberrations in acutely treated hamster bone marrow cells." | ( Georgieva, V; Kappas, A; Tziolas, V; Tzoneva, M; Vachkova, R, 1985) |
| "In addition, chromosomal aberrations (chromatid breaks and translocations) were induced by the treatment of Friend and L 1210 leukemia cells with CNMoADM at concentrations between 0." | ( Groth, G; Marquardt, H; Steinheider, G; Westendorf, J, 1985) |
| "NiCl2 was more potent in inducing chromosomal aberrations in cells that were maintained with a salts/glucose medium during metal treatment than when cells were treated in culture growth medium." | ( Costa, M; Sen, P, 1985) |
| "The dose dependences of chromosome aberrations rate were investigated in lymphocytes of oncological patients after cyclophosphamide (CP) administration." | ( Filippova, TV; Kuzin, SM; Stukalov, SV, 1985) |
| "Certain classes of chromosome abnormalities that have been found associated with male sterility in other investigations, namely trisomies, XXY's, and X-autosome translocations, are not expected from treatment of 19A + Y cells when F(1) males are studied." | ( Cacheiro, NL; Russell, LB; Swartout, MS, 1974) |
| "The incidence of chromosome aberrations in rat bone marrow, examined 6 hr after the administration of 7,12-dimethylbenz(a)anthracene, was significantly enhanced by induction of anemia 0-48 hr before the carcinogen treatment and was suppressed by induction of polycythemia." | ( Sugiyama, T, 1971) |
| "Up to 50% of the cells had chromosome abnormalities in number or structure following treatment with asbestos (2." | ( Barrett, JC; Hesterberg, TW; Oshimura, M; Tsutsui, T, 1984) |
| "The frequency of chromosome aberrations was significantly increased in patients treated with both the triple drug combinations, i." | ( Ahuja, YR; Jaju, M, 1983) |
| "The induction of chromosomal aberrations and gene mutations was studied in Chinese hamster cells after separate and combined treatment with BUdR and SV40." | ( Gorbunova, LV; Lukash, LL; Marshak, MI; Shapiro, NI; Varshaver, NB, 1980) |
| "The frequency of chromosomal aberrations induced by fast neutrons (which predominantly induce DNA double-strand breaks) was not influenced by post-treatment with NE." | ( Natarajan, AT; Zwanenburg, TS, 1982) |
| "The conclusion was made that chromosome aberrations are not the single reason for the death of the mutant flies after mutagenic treatment and that the function of the mus(2)201G1 gene is necessary for divided and undivided cells." | ( Levina, VV; Sharygin, VI, 1984) |
| "To study chromosomal aberrations and the frequency of sister-chromatid exchanges (SCE) a long-term chronic toxicity study was performed in rats treated with phenacetin, phenazone and caffeine, alone and in different combinations." | ( Granberg-Ohman, I; Hjerpe, A; Johansson, S, 1980) |
| "The highest number of chromosome aberrations and alterations, including an increase in heteroploidy, was also noticed in the bone marrow cells of the mice whose tumors were treated simultaneously with MIS + delta + X." | ( Banerjee, R; Goldfeder, A; Mitra, J, 1983) |
| "However, significant induction of chromosomal aberrations was not observed in the mesenchymal cells from DEN-treated groups." | ( Böning, W; Emura, M; Mohr, U; Richter-Reichhelm, HB; Tsuda, H, 1983) |
| "The rate of cells with chromosome aberrations increased as the benzene level was raised (upon both administration routes) and was satisfactorily depicted by linear equations." | ( Fel'dt, EG; Kosiakov, VV; Zhurkov, VS, 1983) |
| "The frequency of consistent structural chromosome aberrations was determined for 108 fetuses (day 14 of gestation) from 20 female rabbits treated before conception with 90 micrograms/kg of streptonigrin (NSC-45383)." | ( DuFrain, RJ; Huff, VD; Hutton, D; Littlefield, LG; Morrison, WD, 1984) |
| "Identical chromosome abnormalities were present in cell lines that arose in control, dimethyl sulfoxide-treated, or 7, 12-dimethylbenz[a]anthracene-treated cultures." | ( Cowell, JK, 1980) |
| "Aneuploidy, tetraploidy, and chromosome aberrations increased significantly in the hepatic cells of DMN-treated animals in vivo, with no significant change over the 7- to 35-week period." | ( Ockey, CH; Swindell, JA, 1983) |
| "In the treated series, the incidence of chromosome aberrations was significant at all dose levels." | ( Nandan, SD; Rao, MS, 1982) |
| "The frequency of cells with chromosome aberrations in the lymphocyte culture of the patients before the treatment was significantly higher than that in the healthy donors." | ( Akulenko, TV, 1981) |
| "A few severe chromosome aberrations, such as dicentrics or translocations, appeared in the control animals as well as in the lead-treated ones, during the course of the experiment." | ( Jacquet, P; Tachon, P, 1981) |
| "Various nuclear and chromosomal aberrations such as, fragmentation of the chromosomes, extreme clumping and unequal groupings of the chromosomes, vacuolization of nuclei and nucleoli, and irregular anaphase chromatid breaks, were observed in the materials treated with 500 and 750 micrograms/ml streptomycin, and 250 and 500 micrograms/ml tetracycline, and which, however, were not seen with any of the concentrations of penicillin employed." | ( Sarma, YS; Srivastava, S, 1980) |
| "The induction of chromosome aberrations by the crosslinking agents mitomycin C (MMC) and cisplatin (DDP), the SN-1 type alkylating agents N-ethyl-N'-nitro-N-nitrosoguanidine (ENNG), methyl nitrosourea (MNU), and ethyl nitrosourea (ENU), and the SN-2 type alkylating agent ethyl methanesulfonate (EMS), but not by the SN-1 type alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and the SN-2 type alkylating agent methyl methanesulfonate (MMS), was suppressed by post-treatment with DHA, DPA, and EPA." | ( Sakaguchi, M; Sasaki, YF; Shirasu, Y; Yamada, H; Yamagishi, T, 1994) |
| "The mitotic index and the frequency of chromosomal aberrations were analysed at three sample times (3, 6 and 24 h) after a single intraperitoneal treatment." | ( Anitha, B; Durairaj, G; Gopinath, PM; Sudha, S, 1994) |
| "This cell cycle dependency of chromosome aberrations induced by postirradiation hypertonic treatment was the same as that of cell survival." | ( Kaneko, I; Koide, F; Kosaka, T; Nakano, K; Tanaka, S; Tsukahara, M, 1995) |
| "No increase in the frequency of chromosome aberrations was elicited in cultures treated for 1-3 weeks with NaF over the range of doses examined." | ( Hamaguchi, F; Matsudo, Y; Someya, T; Takahashi, M; Tanaka, Y; Tsutsui, T; Uehama, A; Yamamoto, H, 1995) |
| "The frequency of chromosome aberrations induced by mitomycin C or bleomycin was not changed by o-vanillin treatment." | ( Matsumura, H; Ohta, T; Watanabe, K, 1993) |
| "Enhancement of the induction of chromosome aberrations by MMC was observed when cells were treated with organotins during the G2 phase." | ( Kinae, N; Sasaki, YF; Sugiyama, C; Yamada, H, 1993) |
| "Enhancement of chromosome aberrations induced by MMC was observed when CHO K1 cells were treated with Cd2+ during the G1 phase." | ( Miyahara, T; Sasaki, YF; Yamada, H, 1993) |
| "The in vivo endpoint was chromosomal aberrations in the bone-marrow cells of mice following intraperitoneal administration of benzidine and its derivatives." | ( Brezzell, MD; Das, SK; Espadas-Torre, MC; Hooberman, BH; Sinsheimer, JE; You, Z, 1993) |
| "DNA strand breaks and chromosomal aberrations (CAs) were studied in human cells treated with hydrogen peroxide or with ionizing radiation." | ( Brás, A; Cristóvão, L; Mexia, J; Pires, V; Rueff, J; Sá da Costa, M, 1993) |
| "Inducibility of chromosome aberrations of the cells following treatment with NaF was also dependent upon the phase of the cell cycle." | ( Hayashi, N; Tsutsui, T, 1993) |
| "The frequency of chromosomal aberrations and sister-chromatid exchanges (SCEs) did not show any statistically significant differences in the patients before treatment and after exposure to combined HRZ therapy as compared to controls (p > 0." | ( Ekmekçi, A; Sayli, A, 1995) |
| "A strong increase of radiation-induced chromosomal aberrations was observed in normal and HzAT cells post-treated with ara-C, APC and HU, but not in the presence of BuPdG." | ( Antoccia, A; Catena, C; Palitti, F; Raggi, T; Tanzarella, C, 1994) |
| "The enhancing effects of arsenite on chromosome aberrations and cell destruction induced by UV were also reduced by a 2-h pretreatment with GSH." | ( Huang, CF; Huang, H; Jan, KY; Jinn, CM; Wu, DR, 1993) |
| "The incidence of chromosome abnormalities in melphalan-treated cells (25%) was higher than in the control group (17%)." | ( Friberg, LG; Granberg, S; Islam, MQ; Köpf, I; Levan, A; Levan, G, 1993) |
| "Different chromosomal aberrations were detectable directly in the pulsed field gel when growing yeast cells were incubated with a genotoxin for 6 h at 26 degrees C followed by treatment with the genotoxin for another twelve days at 4 degrees C." | ( Fahrig, R; Steinkamp-Zucht, A, 1995) |
| "The incidence of chromosomal aberrations in cells treated with the short fibre sample was similar to control levels; the long amosite sample caused significantly more chromosomal aberrations than the short fibre sample." | ( Donaldson, K; Golyasnya, N, 1995) |
| "An effective induction of chromosomal aberrations after restrictase treatment was observed." | ( Dimitrova, A; Gecheff, KI; Mirkova, VN; Stoilov, LM; Uzunova, V, 1996) |
| "Complex chromosomal abnormalities did not improve following chemotherapy." | ( Fukumura, R; Ide, K; Isobe, H; Matsuoka, R; Nagoshi, H; Nomura, M; Saito, N; Takahashi, A; Takahashi, S; Yamakawa, T, 1996) |
| "Structural chromosomal aberrations and mitotic indices increased after treatment with the nitrosamine precursors for all tested times." | ( el Ghor, AA; el-Shazly, MM; Moharram, NZ; Tohamy, AA, 1996) |
| "The frequency of chromosomal aberrations (CA) and sister chromatid exchanges (SCE) in peripheral lymphocytes increased significantly after 12 weeks of treatment and remained elevated after 48 weeks treatment in peripheral lymphocytes." | ( Nordenson, I; Rantapää Dahlqvist, S, 1996) |
| "Significantly elevated frequencies of chromosomal abnormalities caused by postirradiation treatment with hypertonic contrast agents appeared to increase with increasing hypertonicity." | ( Iwasawa, T; Kong, ZS; Kubota, N; Kurihara, H; Matsubara, S; Omura, M; Torigoe, S; Yoshida, T, 1997) |
| "Marshal increased the number of chromosomal aberrations (CA) per cell, and the number of cells with abnormalities, at all concentrations and treatment times." | ( Ila, HB; Rencüzoğullari, E; Topaktaş, M, 1996) |
| "Sperm chromosome abnormalities were assessed in testicular cancer patients before and after treatment with BEP (bleomycin, etoposide, cisplatin)." | ( Barclay, L; Ernst, S; Ko, E; Martin, RH; Rademaker, A; Summers, N, 1997) |
| "To determine the incidence of chromosomal abnormalities in normally androgenized infertile men with no other recognized causes of infertility or who had ever been submitted to other unsuccessful methods of treatment." | ( Bonaccorsi, AC; Botler, J; Franco Júnior, JG; Martins, RR; Vargas, F, 1997) |
| "This sample clearly increased chromosomal aberrations also when tested as a concentrate (4-h treatment), which showed that the observed clastogenicity was not unspecifically due to the relatively large volumes used in the treatments with the unconcentrated liquors." | ( Jäppinen, P; Norppa, H; Rosenberg, C; Rudek, Z; Sipi, P; Vainio, H, 1997) |
| "A statistically significant level of chromosomal aberrations was elicited in SHE cells treated with phenolphthalein at the highest dose (40 microM)." | ( Barrett, JC; Hamaguchi, F; Hasegawa, K; Someya, T; Tamura, Y; Tanaka, Y; Tsutsui, T; Uehama, A; Yagi, E; Yamamoto, H, 1997) |
| "CsCl induced chromosomal aberrations in frequencies directly proportional to the dose administered." | ( Ghosh, A; Ghosh, AK; Sharma, A; Talukder, G, 1991) |
| "Clonogenic survival and chromosomal aberrations were measured in parallel in endothelial cells treated with desferrioxamine after increasing doses of gamma radiation." | ( Juckett, MB; Klein, JP; Shadley, JD; Zheng, Y, 1998) |
| "PQ clearly induced cytotoxicity and chromosome aberrations but did not induce gene mutations at the HPRT locus or increased DNA migration in the comet assay under the same treatment conditions." | ( Hartmann, A; Haupter, S; Speit, G, 1998) |
| "After 24 h, chromosomal aberrations were studied in the bone marrow of the femur by routine metaphase preparation after colchicine treatment." | ( Bisht, KS; Devi, PU; Vinitha, M, 1998) |
| "In present studies the development of chromosomal aberrations, micronuclei in bone marrow cells and sperm head abnormalities were used as mutagenic bioassay in Swiss albino mice treated with cisplatin alone or ascorbic plus cisplatin." | ( Giri, A; Khynriam, D; Prasad, SB, 1998) |
| "Sperm chromosomal abnormalities were assessed in testicular cancer patients before, during, and after BEP (bleomycin, etoposide, cisplatin) chemotherapy (CT)." | ( Barclay, L; Ernst, S; Ko, E; Martin, RH; Rademaker, A; Summers, N, 1999) |
| "The frequencies of structural chromosomal aberrations were analyzed in peripheral blood lymphocytes of 31 chronic alcoholics at the beginning of an intensive outpatient treatment program at a neuropsychiatric clinic and were compared with 31 controls matched for gender, age, smoking habits, and nondrinkers." | ( Ehrenreich, H; Hüttner, E; Matthies, U; Nikolova, T, 1999) |
| "Cocaine treatments per se induced a few chromosome aberrations while treatments of cocaine plus S9 caused a significant increase in chromosome aberrations." | ( Lee, TC; Li, JH; Wang, TC; Yu, RC, 1999) |
| "Genotoxic effects were assessed through chromosome aberrations (CA), micronucleated erythrocytes (MNE), mitotic index (MI) and sperm head anomaly (SHA) studies, keeping suitable succussed alcohol fed (positive) and As2O3 untreated normal (negative) controls." | ( Bukhsh, AR; Datta, S; Mallick, P, 1999) |
| "The frequency of anaphase chromosome aberrations (bridges or/and fragments) in rats exposed to X-rays or treated with cyclophosphamide was estimated: in proliferating hepatocytes (2 Gy) as a function of time during liver regeneration after partial hepatectomy; in bone marrow cells (2." | ( Vorobtsova, IE, 2000) |
| "Incidence of structural chromosome aberrations in each treatment was 34." | ( Kamiguchi, Y; Tateno, H, 1999) |
| "Some estrogen metabolites induced chromosome aberrations in SHE cells following treatment for 24 hr." | ( Barrett, JC; Tamura, Y; Tsutsui, T; Yagi, E, 2000) |
| "MMC did not induce chromosome aberrations in either cell line treated in G(2) but did with the same effectiveness in both cell lines treated in S-phase." | ( Allio, T; Donner, EM; Preston, RJ, 2000) |
| "The incidence of chromosome aberrations was not affected by co-treatment with alpha-naphthoflavone, an inhibitor of 2-hydroxylase that inhibits oxidative conversion of 2-MeOE(2) to 2-hydroxyestradiol, but the incidence was slightly increased by co-treatment with L-ascorbic acid." | ( Barrett, JC; Hagiwara, M; Hikiba, H; Kubo, C; Miyachi, T; Tamura, Y; Tsutsui, T, 2000) |
| "The different types of structural chromosomal aberrations, including gaps, breaks, deletions and fragments were increased in epirubicin-treated cultures." | ( El-Mahdy Sayed Othman, O, 2000) |
| "The clinical significance of complex chromosome aberrations for adults with acute myeloid leukaemia (AML) was assessed in 920 patients with de novo AML who were karyotyped and treated within the German AML Cooperative Group (AMLCG) trials." | ( Büchner, T; Fonatsch, C; Haase, D; Haferlach, T; Heinecke, A; Hiddemann, W; Löffler, H; Sauerland, MC; Schlegelberger, B; Schoch, C; Staib, P, 2001) |
| "The end points investigated were chromosomal aberrations and mitotic index at 24 hours posttreatment and micronuclei (MN) at 30 hours posttreatment in bone marrow cells of male and female mice after a single intraperitoneal exposure." | ( Choudhury, RC; Das, B; Jagdale, MB; Misra, S, 2000) |
| "Induction of chromosome aberrations in V79 cells after a one hour pulse treatment with AFB1 and G1 plus S9 mix was also studied." | ( Batt, TR; Chen, HH; Hsueh, JL; Huang, CC, 1980) |
| "High frequencies of chromosomal aberrations were detected in spermatocytes within 64 h after treatment when over 30% of the metaphases analyzed had structural aberrations (P < 0." | ( Bishop, JB; Generoso, WM; Hozier, J; Lowe, X; Marchetti, F; Wyrobek, AJ, 2001) |
| "In contrast, NDMA did not induce chromosome aberrations in human spermatozoa by S9 treatment, although positive results have been observed in somatic cells." | ( Kamiguchi, Y; Watanabe, S, 2001) |
| "At 24 hrs post-treatment the induced chromosomal aberrations, mostly chromatid breaks and fragments, by all the three different concentrations of 5-FU were found statistically significant." | ( Choudhury, RC; Jagdale, MB; Misra, S; Palo, AK, 2001) |
| "The occurrence of chromosomal aberrations (CA), sister chromatid exchanges (SCE) and micronuclei (MN) was observed after the treatment of cells by different concentrations (0." | ( Bozsakyová, E; Chalupa, I; Sebová, L; Slamenová, D, 2001) |
| "Patients with 'high-risk' chromosomal abnormalities may particularly benefit from this treatment." | ( Andre, M; Bosly, A; Ferrant, A; Kunzmann, R; Lübbert, M; Ravoet, C; Verhoef, G; Wijermans, P, 2001) |
| "In the chromosomal aberrations assay, the treatments were either 3 or 19 h without metabolic activation." | ( Donner, M; Murli, H; Warheit, DB, 2001) |
| "A significant suppression in the chromosomal aberrations was recorded following pretreatment with 2." | ( Shukla, Y; Taneja, P, 2002) |
| "To investigate the induction of chromosome aberrations (CA) in mouse bone marrow cells by sulfur dioxide (SO(2)) inhalation, mice were treated by SO(2) exposure for 4 h/day for 7 days at various concentrations of SO(2), then mitotic indices and CA in mouse bone marrow cells were analyzed." | ( Meng, Z; Zhang, B, 2002) |
| "Structural chromosome aberrations were observed in 10-20% of eggs following treatments during telophase II, but there was no increased incidence of aneuploidy in treatments during this meiotic stage." | ( Kamiguchi, Y; Tateno, H, 2002) |
| "However, a lower percentage of chromosome aberrations was observed when animals were treated with the therapeutic dose for 30 consecutive days." | ( Aly, FA; Donya, SM, 2002) |
| "The frequencies of chromosomal aberrations (CAs) and sister chromatid exchanges (SCEs) were determined in peripheral blood lymphocyte cultures from women with breast cancer treated by chemotherapy (CT) with FEC (5-fluorouracil, epirubicin, and cyclophosphamide) or CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) cocktail in six CT cycles." | ( Carrara, HH; Silva, LM; Takahashi, CS, 2002) |
| "CP-induced chromosomal aberrations (CAs) in bone marrow were decreased in vitamin E pretreated mice, but significantly (P < or = 0." | ( Choudhury, RC; Jagdale, MB, 2002) |
| "To analyse the correlation between chromosomal aberrations and sister-chromatid exchanges (SCE) in cells treated in G1 phase with X-rays or DNaseI." | ( Obe, G; Sayed Aly, M; Schunck, C; Wojcik, A, 2002) |
| "Measurements of chromosomal aberrations were made in 10 thalassaemia major patients treated long-term with deferiprone (at least 5 years) and compared with an equal number of patients matched for age, sex and iron overload, treated long-term with deferoxamine." | ( Galanello, R; Kirkland, D; Leoni, G; Marshall, R; Minto, S; Spino, M; Tricta, F, 2003) |
| "The production of chromosome aberrations by cyanide proved to be practically unaffected by the temperature during treatment." | ( KIHLMAN, BA, 1957) |
| "To measure chromosomal aberrations in blood lymphocytes from breast cancer patients treated with radiotherapy after quadrantectomy or tumorectomy." | ( Canale Cama, G; Cella, L; d'Alesio, V; Durante, M; Gialanella, G; Grossi, G; Pacelli, R; Pugliese, M; Punzo, G; Salvatore, M; Sardi, I; Scampoli, P; Solla, R, 2003) |
| "Anecdotal cases of chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases have been reported in patients with chronic myelogenous leukemia (CML) in the chronic phase during treatment with interferon and, more recently, with imatinib." | ( Cortes, J; Garcia-Manero, G; Giles, F; Hayes, K; Kantarjian, H; Medina, J; O'Brien, S; Rios, MB; Talpaz, M, 2003) |
| "Mitotic abnormalities and chromosomal aberrations were evaluated after 6-h treatment and 24-h recovery period." | ( Besendorfer, V; Kalafatić, M; Kopjar, N, 2004) |
| "We determined chromosome aberrations (CAs) and sister chromatid exchanges (SCEs) as well as the mitotic index (MI) and cell viability following OTA and ZEA treatment." | ( Barbieri, R; Lioi, MB; Salzano, S; Santoro, A; Ursini, MV, 2004) |
| "Metaphase analysis for chromosomal aberrations (CA) and micronucleus (MN) assay in cytokinesis-blocked cells have been performed in peripheral blood lymphocytes from 19 healthy male twins (9 monozygotic and 10 dizygotic pairs), aged 70-78 years, after APC, BLM and APC+BLM treatments." | ( Argentin, G; Caporossi, D; Cicchetti, R; Parisi, P; Pittaluga, M; Tedeschi, B; Vernole, P, 2004) |
| "Data from two studies of chromosomal aberrations in astronauts used blood samples obtained before and after space flight, and a third study used blood samples from patients before and after radiotherapy course." | ( Ando, K; Cucinotta, FA; Durante, M; Furusawa, Y; George, K; Obe, G, 2004) |
| "Several cases of emergence of clonal chromosomal abnormalities after therapy with imatinib have been reported, but their incidence, etiology and prognosis remain to be clarified." | ( Auger, N; Bastie, JN; Castaigne, S; Charrin, C; Dastugue, N; Eclache, V; Flandrin, G; Gervais, C; Giraudier, S; Imbert, M; Lafage-Pochitaloff, M; Laurent, G; Leonard, C; Lessard, M; Leymarie, V; Maarek, O; Maloisel, F; Mossafa, H; Mozziconacci, MJ; Mugneret, F; N'Guyen Khac, F; Nicolini, F; Recher, C; Rousselot, P; Roussi, J; Roux, GL; Salles, B; Talmant, P; Terre, C; Van den Akker, J; Vernant, JP; Vey, N; Vigier, M; Viguié, F; Yacouben, Y, 2004) |
| "DFSPs have specific chromosomal abnormalities involving the platelet-derived growth factor beta-chain locus (PDGFB) which may render these tumors responsive to targeted therapy with the tyrosine kinase inhibitor imatinib mesylate." | ( Fletcher, JA; Labropoulos, SV; Oliveira, AM; Papadopoulos, S; Razis, ED, 2005) |
| "The frequency of chromosomal aberrations observed during the course of therapy was related to the blood dose." | ( Kampen, WU; Nosske, D; Roos, H; Stephan, G, 2005) |
| "The emergence of clonal chromosomal abnormalities in Philadelphia-negative cells during treatment with imatinib in patients with Philadelphia-positive chronic myeloid leukemia has been reported." | ( Alonso, E; Boqué, C; Domingo, A; Espinet, B; Oliveira, AC; Solé, F, 2005) |
| "The number of chromosome aberrations induced by dioxidine or cadmium chloride in vitro at the G2 stage decreased on days 14 and 30 of treatment with the complex." | ( Beketova, NA; Bochkov, NP; Chebotarev, AN; Durnev, AD; Katosova, LD; Kodentsova, VM; Platonova, VI; Sidneva, ES, 2005) |
| "Some breaks were manifested as chromosomal aberrations when the G2 checkpoint of CNDAC-arrested cells was abrogated by UCN-01 but also in a minor population of cells that escaped to mitosis during treatment with CNDAC alone." | ( Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W, 2005) |
| "Analysis of chromosome aberrations using FISH (fluorescence in situ hybridization) revealed a high frequency of aberrant cells and color junctions in the caffeine-treated cells." | ( Cucinotta, FA; George, K; Ito, H; Kan'o, M; Kawata, T; Liu, C; Okayasu, R; Saito, M; Uno, T, 2005) |
| "No increase in chromosomal aberrations was found after combined treatment, but a significantly enhanced number of fragmented nuclei were observed when confluent cultures were replated after allowing PLDR." | ( Bergs, JW; Franken, NA; Haveman, J; ten Cate, R; van Bree, C, 2006) |
| "The appearance of chromosomal aberrations shown by G-banding during 6-MP therapy in some JMML cases may result, in part, from the growth of a 6-MP-refractory clone that already exists at onset." | ( Asami, K; Hidaka, E; Kamijo, T; Koike, K; Matsuda, K; Matsuzaki, S; Miki, J; Nakazawa, Y; Sakashita, K; Sano, K; Yanagisawa, R, 2006) |
| "induced structural and numerical chromosomal aberrations in bone marrow and germ cells of male mice, whereas, honey treatment reduced the genotoxicity of mycotoxins." | ( Abd El-Khalek, AB; Ezz El-Arab, AM; Girgis, SM; Hegazy, EM, 2006) |
| "The prognostic value of chromosomal abnormalities was studied in untreated multiple myeloma patients who were registered into a prospective randomised multicentre phase 3 study for intensified treatment (HOVON24)." | ( Beverloo, B; Lokhorst, HM; Poddighe, PJ; Segeren, CM; Sonneveld, P; Steijaert, MM; van der Holt, B; Verhoef, GE; Westveer, PH; Wu, KL, 2007) |
| "Increased frequency of chromosome aberrations in recipient cells treated with conditioned medium from irradiated but not from un-irradiated donor cells was observed which was independent of radiation type." | ( Funayama, T; Hamada, N; Kakizaki, T; Kanasugi, Y; Kobayashi, Y; Sakashita, T; Takakura, K; Wada, S, 2007) |
| "Its latency, cytogenetic aberrations, and clinical features are thought similar to, or identical with, AML resulting from the use of modern day cytotoxic agents for chemotherapy and immunotherapy." | ( Natelson, EA, 2007) |
| "The development of chromosomal abnormalities (CAs) in the Philadelphia chromosome (Ph)-negative metaphases during imatinib (IM) therapy in patients with newly diagnosed chronic myecloid leukemia (CML) has been reported only anecdotally." | ( Abruzzo, LV; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Verstovsek, S, 2007) |
| "The data obtained in the chromosome aberrations (CA) test showed a significant reduction in CA frequency in the cultures treated with DXR and extract in comparison with those that received only DXR during the cell cycle phases G1 and S and throughout the entire cycle, as well as the absence of mutagenicity in all the treatments realized." | ( Barcelos, GR; Cólus, IM; Maciel, MA; Mori, MP; Shimabukuro, F, 2007) |
| "For all the chromosome aberrations considered, a negative correlation between their initial yield and the percentage of this yield remained 12 months after radiotherapy was observed (p < 0." | ( Barquinero, JF; Barrios, L; Caballín, MR; Craven-Bartle, J; de Vega, JM; Ribas, M; Xunclà, M, 2008) |
| "For analysis of chromosomal aberrations, both single and repeated oral treatments for a period of 3 weeks were performed." | ( Fahmy, MA; Farghaly, AA; Hassan, EE; Hassan, NH, 2008) |
| "We analyzed chromosome aberrations (CAs) and sister chromatid exchanges (SCEs) as well as the mitotic index (MI) and cell viability after the treatments with verminoside and verbascoside." | ( Aquino, RP; Autore, G; Bianco, G; Bifulco, M; Gazzerro, P; Lioi, MB; Marzocco, S; Picerno, P; Santoro, A, 2008) |
| "SE5-OH was negative for chromosome aberrations in Chinese hamster lung cells up to 3,000 microg/ml with and without metabolic activation and did not induce increases in micronucleated polychromatic erythrocytes taken from Sprague-Dawley rats administered (via gavage) up to 4,000 mg/kg SE5-OH twice daily for two consecutive days." | ( Burdock, GA; Enomoto, Y; Hamada, S; Itoh, T; Kurata, Y; Narumi, K; Shimomura, Y; Ueno, T; Yee, S, 2008) |
| "There were high numbers of chromosomal aberrations in all amiodarone-treated groups, compared with negative controls." | ( Almeida, MR; Antunes, LM; Campos, MG; da Silva, VJ; de Oliveira Lima, E; Dias, FL; Salman, AK, 2008) |
| "To analyze the effect of additional chromosome abnormalities on the prognosis and the clinical manifestations of acute promyelocytic leukemia (APL) and the reaction of the patients with additional chromosomes to the treatment of combination of red arsenic sulfide, all trans-retinoic acid (ATRA) and anthracyclin." | ( Bao, L; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lin, W; Liu, YR; Lu, J; Lu, XJ; Zhang, Y, 2008) |
| "There were no chromosome aberrations both in the honey treated as well as distilled water treated (negative control) cell lines." | ( Abdullah, SF; Ahmad, A; Ali, AQ; Kannan, TP, 2009) |
| "HM10760A did not induce chromosomal aberrations either in the short-period (6 hours) test with or without rat-liver S9 mix or in the continuous-treatment (24 hours) test." | ( Han, JY; Kim, JY; Koh, WS; Kwon, SC; Lee, GS; Lee, M; Lee, YM, 2010) |
| "The yield of chromosome aberrations increased during the therapy course, and the frequency was lower in patients irradiated with carbon ions as compared to patients treated with IMRT with similar target volumes." | ( Debus, J; Durante, M; Fournier, C; Hartel, C; Lee, R; Nasonova, E; Nikoghosyan, A; Ritter, S; Schulz-Ertner, D; Sommer, S, 2010) |
| "Moreover, no apparent chromosomal aberrations were observed in mammalian bone marrow cells treated with SAA." | ( Cai, Y; Gao, P; Jin, J; Liu, B; Tian, X; Zhang, H, 2009) |
| "Additional chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia are non-random and strongly associated with disease progression, but their prognostic impact and effect on treatment response is not clear." | ( Bommer, C; Daniel, P; Dörken, B; Kim, TD; Koca, G; le Coutre, P; Nogai, H; Schwarz, M; Türkmen, S, 2010) |
| "Natamycin [corrected] did not induce chromosome aberrations but significantly increased the number of micronucleated polychromatic erythrocytes in bone marrow and sperm head abnormalities at all concentrations and treatment periods." | ( Kaymak, F; Rasgele, PG, 2010) |
| "Incidence of structural chromosome aberrations in ICSI zygotes derived from M beta CD-treated spermatozoa was similar to that in zygotes produced by in vitro fertilization (IVF) with the same spermatozoa, but significantly lower compared to ICSI zygotes derived from acrosome-intact spermatozoa." | ( Tateno, H, 2010) |
| "The results of chromosomal aberrations assay showed that ZER was not clastogenic, when compared to untreated control, meanwhile MN test results showed a dose-dependent increase in MN formation." | ( Abdul, AB; Al-Zubairi, AS; Syam, MM, 2010) |
| "Similarly, NHE-water did not induce chromosome aberrations in Chinese hamster lung fibroblast cells (CHL/IU), in short-term (6-hour) tests, with or without rat liver S9, or in a continuous treatment (24-hour) test." | ( Harata, Y; Miwa, N; Mizuhashi, F; Nakajima, M; Saitoh, Y, 2010) |
| "Interestingly, rare balanced chromosomal abnormalities were observed in the present cases, thus providing new insights into the leukemogenesis of therapy-related leukemia." | ( Ise, M; Kumagai, K; Mimura, N; Nagata, M; Sakai, C; Takagi, T; Tsujimura, H, 2010) |
| "The present study suggests that chromosomal aberrations observed in the embryos did not the affect their development until adulthood but could make the progeny of the tamoxifen treated males vulnerable to the development of adult onset diseases later in life." | ( Balasinor, NH; Kedia-Mokashi, N; Makawy, AE; Saxena, M, 2010) |
| "The rate of chromosomal aberrations was normal in AOA2 cells after treatment with CPT, MMC, H₂O₂ and X-rays." | ( Chessa, L; De Amicis, A; Delia, D; Fanciulli, M; Ferrari, F; Piane, M, 2011) |
| "An increased number of chromosomal aberrations were observed after pre-treatment with PB." | ( Aiub, CA; Eckl, P; Felzenszwalb, I; Ferreira, F; Gadermaier, G; Oliveira, I; Ribeiro Pinto, LF, 2011) |
| "Although various forms of chromosomal abnormalities have been detected in approximately 50-60% of patients with de novo MDS and in up to 80% of patients with therapy-related MDS, their molecular significance for pathogenesis and disease progression is not yet fully understood." | ( Horiike, S; Kuroda, J; Nagoshi, H; Taniwaki, M, 2011) |
| "DNA damage, micronuclei, chromosomal aberrations, and sister chromatid exchanges were analyzed in F344 rats treated with furan for up to 28 days." | ( Dekant, W; Fiore, M; Malfatti, M; Mally, A; Mosesso, P; Neuwirth, C; Pepe, G; Turteltaub, K, 2012) |
| "Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described." | ( Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R, 2013) |
| "Additional chromosomal abnormalities (ACAs) in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) are strongly associated with disease progression, but their prognostic impact and effect on treatment response are not clear." | ( Bektas, O; Bozkurt, S; Buyukasik, Y; Goker, H; Inanc, A; Kansu, E; Uz, B, 2013) |
| "Additional chromosomal aberrations affecting the p53-p21 and CDK4-pRB axes compound the effects of MYCN on the G(1) checkpoint and reduce sensitivity to cell death after doxorubicin treatment." | ( Bannert, S; Becker, G; Bell, E; Brueckner, LM; Dreidax, D; Ehemann, V; Gogolin, S; Nolte, I; Savelyeva, L; Westermann, F, 2013) |
| "The number (mean ± SE) of chromosomal aberrations in pinealectomized (PINX) animals treated with melatonin and CP (2." | ( Amaral, FG; Berra, CM; Bordin, S; Cipolla-Neto, J; Curi, R; Ferreira, SG; Peliciari-Garcia, RA; Rodrigues, AC; Takahashi-Hyodo, SA, 2013) |
| "Cytogenetic biomarkers such as chromosome aberrations (CAs), sister chromatid exchanges (SCEs) and cytochalasin-B blocked micronuclei (CBMN), were studied in blood lymphocytes treated with radiation, or antineoplastic agent (MMC), and APG." | ( Sharma, NK, 2013) |
| "Diagnostic clonal chromosomal abnormalities provide important prognostic information and are among the most important factors in predicting initial response to chemotherapy, duration of remission and overall survival." | ( Appaji, L; Madhumathi, DS; Mir Mazloumi, SH, 2013) |
| "Sister chromatid exchanges (SCEs), chromosomal aberrations (CAs) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels were measured in cultured human blood lymphocytes treated with PAC (10 µM) and/or vitamin B12 (2." | ( Al-Azzam, S; Alzoubi, K; Khabour, O; Khader, M; Mhaidat, N, 2014) |
| "The treated meristems showed chromosome aberrations including sticky metaphases, sticky anaphases, laggard, anaphase bridges, micronuclei, polyploidy, fragments, breaks, and C-mitosis." | ( Aarey, A; Jahan, P; Mohammed, KP; Tamkeen, S, 2015) |
| "As2O3-induced significant chromosome aberrations (CAs) in all treatment groups compared with the control." | ( Bhattacharya, S; Chakraborty, A; Chattopadhyay, A; Srivastava, R, 2015) |
| "Reduction in hematopoietic aplasia and chromosomal aberrations, besides, early recovery in bone marrow and spleen of G-002M pretreated mice, could be attributed to its free radical scavenging, DNA protecting and apoptotic proteins modulating ability against radiation." | ( Gupta, ML; Verma, S, 2015) |
| "The detection of chromosomal abnormalities has a certain reference value for the treatment of primary MM." | ( Guo, HF; Shen, YF; Sun, C; Wang, J; Zhou, X, 2017) |
| "In addition, the chromosome aberrations including chromosome breaks, chromatid breaks, and radial structures significantly increased after the combination treatment of VPA and IR." | ( Cai, Z; Feng, Z; Lim, D; Liu, G; Tian, Y; Tian, Z; Wang, H; Zhang, F, 2017) |
| "DRP did not induce the chromosome aberrations and micronucleus frequencies at all concentrations and at all treatment periods." | ( Aydin, M; Bayram, S; Bozkurt, O; Genç, A; Rencüzoğullari, E, 2017) |
| "The number of chromosomal aberrations were increased in the pesticide treated group compared to the negative control group, although significant increase was observed only in the group exposed to higher dose level of pesticide for both 60 and 90 days." | ( Bagri, P; Jain, SK, 2019) |
| "The highest percentage of chromosomal aberrations was produced by the two tested dose 14 days after treatment." | ( Darwish, IAE; Mosallam, SAE, 2019) |
| "To examine the risk for chromosomal aberrations in fetuses of colchicine-treated patients in a large cohort, and to perform a systematic literature review on the subject." | ( Grinshpun-Cohen, J; Sagi-Dain, L; Singer, A, 2021) |
| "To analyse the influence of chromosomal aberrations in addition to t(15;17)(q22;q21) in acute promyelocytic leukaemia (APL) on clinical characteristics and treatment outcomes." | ( Nguyen, CN; Vu, H; Vu, MP, 2022) |
| "Recently, genetic alterations including chromosome abnormalities have been studied as predictive factors and to aid planning for further treatment." | ( Ainthachot, S; Chamgramol, Y; Deenonpoe, R; Pairojkul, C; Sa-Ngiamwibool, P; Thanee, M; Watcharadetwittaya, S, 2022) |
| "As the disease progresses, additional chromosomal abnormalities (ACAs) have been reported, but their prognostic effect and impact on the response to treatment are still unknown." | ( Ansari, S; Verma, M, 2023) |